Back to discover

Protein / target

Apolipoprotein E

Encoded byAPOEP02649Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
19
Research papers

Protein at a glance

Biological role

Phosphatidylcholine-sterol O-acyltransferase activator

Strongest disease association

Coronary Artery Disease

Via encoding gene APOE · Genetic evidence · score 0.95

Research activity

Emerging research

19 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids.

View complete UniProt function annotation

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:2762297, PubMed:6860692, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:1911868, PubMed:6860692). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:12950167, PubMed:1530612, PubMed:1917954, PubMed:20030366, PubMed:20303980, PubMed:2063194, PubMed:2762297, PubMed:7635945, PubMed:7768901, PubMed:8756331, PubMed:8939961). Finally, APOE also has a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:23676495, PubMed:7635945, PubMed:9395455, PubMed:9488694). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:23676495, PubMed:29516132, PubMed:9395455). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:1917954, PubMed:2762297, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:14754908, PubMed:23620513, PubMed:9395455). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:25173806, PubMed:8939961). APOE is also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). Binds to the immune cell receptor LILRB4 (PubMed:30333625). APOE may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074)

Subcellular location

SecretedSecreted, extracellular spaceSecreted, extracellular space, extracellular matrixExtracellular vesicleEndosome, multivesicular body
Domains and Gene Ontology detail (142)

Gene Ontology

  • Cblood microparticle
  • Cchylomicron
  • Cchylomicron remnant
  • Cclathrin-coated endocytic vesicle membrane
  • Ccytoplasm
  • Cdendrite
  • Cdiscoidal high-density lipoprotein particle
  • Cearly endosome
  • Cendocytic vesicle lumen
  • Cendoplasmic reticulum
  • Cendoplasmic reticulum lumen
  • Cextracellular exosome

317 aa · 36 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GOSynaptic signallingGOCell migrationGOGrowth-factor signallingGOImmune signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·APOE is an apolipoprotein, a protein associating with lipid particles, that mainly funct…
  • ·discoidal high-density lipoprotein particle
  • ·high-density lipoprotein particle
  • ·intermediate-density lipoprotein particle

Synaptic signalling

  • ·glutamatergic synapse
  • ·synaptic transmission, cholinergic

Cell migration

  • ·negative regulation of blood vessel endothelial cell migration
  • ·negative regulation of endothelial cell migration

Growth-factor signalling

  • ·negative regulation of platelet-derived growth factor receptor signaling pathway

Immune signalling

  • ·APOE is an apolipoprotein, a protein associating with lipid particles, that mainly funct…
  • ·negative regulation of inflammatory response
  • ·regulation of innate immune response

Transcriptional regulation

  • ·APOE is an apolipoprotein, a protein associating with lipid particles, that mainly funct…
  • ·negative regulation of gene expression
  • ·positive regulation of DNA-templated transcription

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene APOE

Gene-level evidence surfaced through the gene APOEthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Coronary Artery Disease
0.97Well supported

Genetic evidence dominant · Open Targets 0.77

Dementia
0.94Well supported

Genetic evidence dominant · Open Targets 0.63

Alzheimer's Disease
0.89Well supported

Genetic evidence dominant · Open Targets 0.68

Familial hypercholesterolemia
0.88Well supported

Genetic evidence dominant · Open Targets 0.64

Metabolic Syndrome
0.85Well supported

Genetic evidence dominant · Open Targets 0.60

View evidence synthesis (5)
Coronary Artery DiseaseWell supported
0.97
agreement 0.851.00
Genetic71%Animal model18%Literature11%Genetic literaturedup

Open Targets aggregate 0.77 · 3 independent evidence families · 1 not counted as duplicate

DementiaWell supported
0.94
agreement 0.801.00
Genetic86%Literature14%Genetic literaturedup

Open Targets aggregate 0.63 · 2 independent evidence families · 1 not counted as duplicate

Alzheimer's DiseaseWell supported
0.89
agreement 0.781.00
Genetic77%Literature13%Pathway10%RNA expression0%

Open Targets aggregate 0.68 · 4 independent evidence families

Familial hypercholesterolemiaWell supported
0.88
agreement 0.761.00
Genetic70%Animal model21%Literature9%

Open Targets aggregate 0.64 · 3 independent evidence families

Metabolic SyndromeWell supported
0.85
agreement 0.730.97
Genetic66%Animal model22%Literature12%

Open Targets aggregate 0.60 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Coronary Artery Disease0.77
Alzheimer's Disease0.68
Familial hypercholesterolemia0.64
Dementia0.63
late-onset Alzheimers disease0.61
Metabolic Syndrome0.60

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

elevated triglyceridesClinPGxhypertriglyceridemiaClinPGxhemorrhageClinPGxelevated plasma lipidsClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

19 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Nunomura A · Journal of neuropathology and experimental neurology · 2001

Kersten S · The Journal of clinical investigation · 1999

Ossenkoppele R · Brain : a journal of neurology · 2016

Harmon KG · British journal of sports medicine · 2013

Recent

ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.

Raulin AC · Molecular neurodegeneration · 2022

Europe PMC papers linked directly to this protein.